StockNews.AI
MNPR
StockNews.AI
2 days

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

1. Monopar's abstract for ALXN1840 selected for AASLD presentation. 2. Focus on Wilson disease copper balance study presented on November 9, 2025. 3. Company developing late-stage ALXN1840 and various cancer therapies. 4. Forward-looking statements warn of regulatory and market risks. 5. Presentation may enhance visibility among investors and healthcare professionals.

5m saved
Insight
Article

FAQ

Why Bullish?

Positive presentation at AASLD can increase investor interest and market position. Successful data disclosure in conferences historically boosts stock prices.

How important is it?

High relevance due to the significance of Phase 2 results for a rare disease treatment, critical for market potential.

Why Long Term?

Long-term impacts as successful future data could enhance product pipeline viability, akin to past biotech successes like Regeneron following positive earnings and presentations.

Related Companies

REGNAMGNBMY
WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025. Presentation Details: Title: Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate CholinePublication Number: 0073Session: Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary PhysiologyDate: Sunday, November 9, 9:00-9:15 am ESTPresenting Author: Aftab Ala, MBBS, M.D., FRCP, Ph.D. The abstract is currently available on the conference website, and the materials for the oral presentation will be available at www.monopartx.com on November 9, 2025. About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CONTACT: Monopar Therapeutics Inc.Investor RelationsQuan VuChief Financial Officervu@monopartx.com Follow Monopar on social media for updates:    X: @MonoparTx  LinkedIn: Monopar Therapeutics  

Related News